Biography

Dr. Siddappa N. Byrareddy

School of Medicine

Emory University, Atlanta, USA

Research Fellow


Email: siddappa.n.byrareddy@emory.edu, sidhunb@gmail.com


Qualifications

2007 Ph.D., Neurovirology, National Institute of Mental Health and Neurosciences, India

1999 M.Sc., Biotechnology, Bangalore University, India

1997 B.Sc., Chemistry, Zoology, Microbiology, Bangalore University, India


Publications(selected)

  1. Leinen, Z. J., Mohan, R., Premadasa, L. S., Acharya, A., Mohan, M., & Byrareddy, S. N. (2023). Therapeutic potential of cannabis: a comprehensive review of current and future applications. Biomedicines, 11(10), 2630.
  2. Kannan, S. R., Sachdev, S., Reddy, A. S., Kandasamy, S. L., Byrareddy, S. N., Lorson, C. L., & Singh, K. (2022). Mutations in the monkeypox virus replication complex: potential contributing factors to the 2022 outbreak. Journal of Autoimmunity, 133, 102928.
  3. Kannan, S. R., Spratt, A. N., Sharma, K., Chand, H. S., Byrareddy, S. N., & Singh, K. (2022). Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies. Journal of autoimmunity, 126, 102779.
  4. Kumar, N., Acharya, A., Gendelman, H. E., & Byrareddy, S. N. (2022). The 2022 outbreak and the pathobiology of the monkeypox virus. Journal of autoimmunity, 131, 102855.
  5. Kannan, S. R., Spratt, A. N., Cohen, A. R., Naqvi, S. H., Chand, H. S., Quinn, T. P., ... & Singh, K. (2021). Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. Journal of autoimmunity, 124, 102715.
  6. Pandey, K., Thurman, M., Johnson, S. D., Acharya, A., Johnston, M., Klug, E. A., ... & Byrareddy, S. N. (2021). Mental health issues during and after COVID-19 vaccine era. Brain research bulletin, 176, 161-173.
  7. Pathania, A. S., Prathipati, P., Abdul, B. A., Chava, S., Katta, S. S., Gupta, S. C., ... & Challagundla, K. B. (2021). COVID-19 and cancer comorbidity: therapeutic opportunities and challenges. Theranostics, 11(2), 731.
  8. Rothan, H. A., & Byrareddy, S. N. (2020). The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of autoimmunity, 109, 102433.
  9. Singu, S., Acharya, A., Challagundla, K., & Byrareddy, S. N. (2020). Impact of social determinants of health on the emerging COVID-19 pandemic in the United States. Frontiers in public health, 8, 406.
  10. Acharya, A., Kevadiya, B. D., Gendelman, H. E., & Byrareddy, S. N. (2020). SARS-CoV-2 infection leads to neurological dysfunction. Journal of Neuroimmune Pharmacology, 15, 167-173.
  11. Namasivayam, V., Vanangamudi, M., Kramer, V. G., Kurup, S., Zhan, P., Liu, X., ... & Byrareddy, S. N. (2018). The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic. Journal of medicinal chemistry, 62(10), 4851-4883.
  12. Bishnoi, S., Tiwari, R., Gupta, S., Byrareddy, S. N., & Nayak, D. (2018). Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy. Viruses, 10(2), 90.
  13. Byrareddy, S. N., Arthos, J., Cicala, C., Villinger, F., Ortiz, K. T., Little, D., ... & Ansari, A. A. (2016). Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy. Science, 354(6309), 197-202.
  14. Santangelo, P. J., Rogers, K. A., Zurla, C., Blanchard, E. L., Gumber, S., Strait, K., ... & Villinger, F. (2015). Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy–treated macaques. Nature methods, 12(5), 427-432.
  15. Byrareddy SN*,Ayash-Rashkovsky M, Kramer VG,LeeSJ, Correll M, Novembre FJ, Villinger F, Johnson W, Gegerfelt V, Felber FK, and Ruprecht RM. Live Attenuated Rev-Independent Nef¯SIVEnhances Acquisition of Heterologous SIVsmE660 in Acutely Vaccinated Rhesus Macaques. PLoS One. 2013 Sep 30;8(9):e75556.
  16. Pérez-Bercoff L, Kumar-Vudattu N,Byrareddy SN, Maeurer M, Ljungman P. IL-7 response defined by STAT5 phosphorylationin the reconstituting CMV-specific immune system after hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2013 Oct 15. doi:pii: S1083-8791(13)00452-7. 10
  17. Watkins JD, Sholukh AM, Mukhtar MM,Siddappa NB, Lakhashe SK, Kim M, Reinherz EL, Gupta S, Forthal, DN, Sattentau Q, Villinger F, Corti D, Ruprecht RM, for the CAVD Project Group. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.AIDS. 27(9):F13-F20, June 1, 2013.
  18. Bachler BC, Humbert M, Palikuqi B,Siddappa NB, Lakhashe SK, Rasmussen RA, Ruprecht RM. Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol. 2013 Apr;87(8):4403-16
  19. Rasmussen RA*,Siddappa NB*, Lakhashe SK*, Watkins J, Villinger F, Ibegbu C, Florese RH, Robert-GuroffM, Montefiori DC, Forthal DN, O'Connor D, Ruprecht RM; for the Clade C Program Project. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia.AIDS.2012 Jan 14;26(2):149-55 (*Equal first authors)
  20. Siddappa NB, Hemashettar H, Shanmuganathan V, Semenya A, Sweeney ED, Paul KS, Lee SJ, Secor EW, Ruprecht RM.Schistosoma mansoniEnhances Host Susceptibility to Mucosal but not Intravenous Challenge by R5 Clade C SHIV.PLoS Negl Trop Dis: 2011;5(8): e1270(Appeared in journal cover page).
  21. Watkins JD*,Siddappa NB*, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK,Wang W, Novembre FJ, Villinger F, Ibegbu C, Patel K, Corti D, Agatic G, Vanzetta F, Bianchi S, Heeney JL, Sallusto F, Lanzavecchia A, Ruprecht RM. Cross-clade protection with an anti-HIV-1 V3-loop antibody in macaques mucosally challenged with simian-human immunodeficiency virus.PLoS One. 2011 Mar 31;6(3):e18207 (*Equal first authors)
  22. Siddappa NB,Watkins J, Wassermann K,Wang W, KramerVG,Lakhashe S, Santosuosso M, Poznansky M,Novembre FJ, Villinger F, Else J, MontefioriDC, Rasmussen RA, RuprechtRM. R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models.PLoS One. 2010; 21;5(7):e11689.
  23. Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, Ong H, Rasmussen RA, GrissonRD, Wood C, Zhang H, Kankasa C, Amara RR, Else JG, Montefiori D, Novembre,FJ, Ruprecht RM. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carriesenvfrom an infant with recent HIV clade C infection.J Virol2009; 83(3):1422-32.
  24. Siddappa NB, Avinash A, Venkatramanan M, Ranga U.Regeneration of commercial nucleic acid extraction columns without the risk of carryover contamination.BioTechniques2007; 42: 188-92.
  25. Siddappa NB, Venkatramanan M, Venkatesh P, Janki MV, Jayasuryan N, Desai A, Ravi V, Ranga U.Transactivation and signaling functions of Tat are not correlated:biological and immunological characterization of HIV-1 subtype-C Tat protein.Retrovirology2006; 3:53.
  26. Siddappa NB,Dash PK, Mahadevan A, Desai A, Jayasuryan N, Satishchandra P, Ravi V, Shankar SK, Ranga U.Identification of unique B/C recombinant strains of HIV-1 in the southern state of Karnataka, India.AIDS2005; 19: 1426-1429.


Profile Details

https://www.unmc.edu/pharmacology/faculty/byrareddy/index.html
https://scholar.google.com/citations?user=gEXFqFwAAAAJ&hl=en
https://loop.frontiersin.org/people/509500/overview
https://www.researchgate.net/profile/Siddappa-Byrareddy

Free SCIRP Newsletters
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top